Natco Pharma had challenged Israel based Teva Pharmaceutical's patented 20 mg dosage version of Copaxone in US courts.
The agreement between Natco and Mylan states the two would collaborate to market and distribute Copaxone worldwide
Pharmaceutical's patent on Copaxone, which accounts for 50 percent of its profits through sales of USD 4 billion a year, is due to expire in September.
Thus, Teva made an offer to buy out Mylan for 40 billion USD.
Lets keep a watch on Natco.
Update 28th April -
Natco has rejected the offer from Teva. Stock surged 11%]
The agreement between Natco and Mylan states the two would collaborate to market and distribute Copaxone worldwide
Pharmaceutical's patent on Copaxone, which accounts for 50 percent of its profits through sales of USD 4 billion a year, is due to expire in September.
Thus, Teva made an offer to buy out Mylan for 40 billion USD.
Lets keep a watch on Natco.
Update 28th April -
Natco has rejected the offer from Teva. Stock surged 11%]
No comments:
Post a Comment